載入中
Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.
前收盤價
US$3.96
−US$0.06 · -1.49%
盤後
US$3.96
US$0.00 · 0.00%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.
日內區間
目前US$3.96
52週區間
目前US$3.96
盤中時間採用ET。市場資料可能有所延遲。
Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.
日內區間
目前US$3.96
52週區間
目前US$3.96
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 368.6萬 USD | 345.4萬 USD | — | — | — |
| 毛利 | −368.6萬 USD | −345.4萬 USD | — | — | — |
| 研究與開發 | 1.85億 USD | 1.19億 USD | 1.14億 USD | 1.13億 USD | 1億 USD |
| 銷售、一般及管理費用 | 3170.9萬 USD | 3462.5萬 USD | 2802.1萬 USD | 3094.6萬 USD | 3064.7萬 USD |
| 營業費用 | 2.13億 USD | 1.51億 USD | 1.44億 USD | 1.46億 USD | 1.31億 USD |
| 利息收入 | 971.7萬 USD | 1587.3萬 USD | 948.6萬 USD | 365.2萬 USD | 39萬 USD |
| 折舊和攤銷 | 216.6萬 USD | 215萬 USD | 214.8萬 USD | 210.6萬 USD | 214.1萬 USD |
| 營業利益 | −2.16億 USD | −1.54億 USD | −1.44億 USD | −1.46億 USD | −1.31億 USD |
| 淨利 | −2.07億 USD | −1.38億 USD | −1.34億 USD | −1.42億 USD | −1.3億 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2455.49萬0.00%2.3兆 USD0.03%US$381.57-0.10%
State Street SPDR S&P Biotech ETFXBI2314.42萬0.23%103.03億 USD0.35%US$151.4-1.54%
iShares Russell 2000 ETFIWM1655.15萬0.02%787.4億 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF876.78萬0.01%954億 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO584.86萬0.04%139.17億 USD0.24%US$353.71-0.86%
iShares Biotechnology ETFIBB513.53萬0.05%108.2億 USD0.44%US$204.26-1.08%
Vanguard Russell 2000 ETFVTWO441.09萬0.02%180億 USD0.06%US$112.27-0.35%
Fidelity Enhanced Small Cap ETFFESM433.64萬0.07%64.1億 USD0.28%US$45.24-0.48%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
